inTRAvent’s Bedside Neuro-Navigation Device Receives FDA 510(k) Clearance
Retrieved on:
Tuesday, September 14, 2021
FDA, Surgery, Medical Devices, Hospitals, Health, Standard of care, Knowledge, Artificial intelligence, Indiana University School of Medicine, Cerebral edema, Education, Neuro, FDA, University of California, Irvine Medical Center, CEO, Technology, Neurosurgery, University, 2D, Caregiver, Professor, Patient, Pressure, EVD, Anatomy, ICU, LinkedIn, Safety, Cerebrospinal fluid, Skull, Brain, Jugular vein, Edwin van der Sar, Medical imaging, Medicine
inTRAvent Medical Partners LP, a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, today announced FDA 510(k) clearance of its SOLOPASS system for aiding in the frontal placement of intra-ventricular catheters.
Key Points:
- inTRAvent Medical Partners LP, a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, today announced FDA 510(k) clearance of its SOLOPASS system for aiding in the frontal placement of intra-ventricular catheters.
- Without the aid of contemporary guidance technologies, these conditions make bedside EVD placement challenging even for highly skilled practitioners.
- SOLOPASS allows caregivers to visualize the ventricular system, deep within the brain, to enable precision planning and guidance.
- inTRAvent Medical Partners is a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve the safety and efficacy of neurosurgical procedures.